Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03207750 · ClinicalTrials.gov registry record · Phase 3
This Study Will Evaluate the Immunogenicity, Reactogenicity and Safety of the Routine Infant Vaccines Pediarix®, Hiberix® and Prevenar 13® When Co-administered With GlaxoSmithKline (GSK) Biologicals' Liquid Human Rotavirus Vaccine (HRV) as Compared to GSK's Licensed Lyophilized Vaccine
A Phase 3 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,280
- Enrollment target
NCT03207750 is a Phase 3 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 1,280 participants.
The verdict
NCT03207750, a Phase 3 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,280 participants
- Enrollment target
Study Summary
The purpose of this study is to assess if there is any immune interference between the Porcine circovirus free (PCV-free) liquid Human rotavirus (HRV) vaccine and routine infant vaccinations currently in use in the US, namely Pediarix®, Hiberix® and Prevenar 13® as compared to the currently licensed lyophilized formulation of the HRV vaccine when co-administered with the same routine vaccinations in healthy infants 6-12 weeks of age
Interventions
- BIOLOGICAL Rotarix
- BIOLOGICAL Pediarix
- BIOLOGICAL Hiberix
- BIOLOGICAL Prevenar 13
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,280 participants |
| Start Date | 2017-09-14 |
| Est. Completion | 2019-03-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03207750
The ClinicalTrials.gov registry entry for NCT03207750 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,280 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Rotarix is the first listed.
NCT03207750 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03207750 about?
NCT03207750 is a clinical study titled "This Study Will Evaluate the Immunogenicity, Reactogenicity and Safety of the Routine Infant Vaccines Pediarix®, Hiberix® and Prevenar 13® When Co-administered With GlaxoSmithKline (GSK) Biologicals' Liquid Human Rotavirus Vaccine (HRV) as Compared to GSK's Licensed Lyophilized Vaccine". The purpose of this study is to assess if there is any immune interference between the Porcine circovirus free (PCV-free) liquid Human rotavirus (HRV) vaccine and routine infant vaccinations currently in use in the US, namely Pediarix®, Hiberix® and Prevenar 13® as compared to the currently licensed...
What is the current status of trial NCT03207750?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,280 participants. The study started on 2017-09-14. Estimated completion is 2019-03-01.
What interventions are being tested in trial NCT03207750?
The interventions under investigation include: Rotarix (BIOLOGICAL), Pediarix (BIOLOGICAL), Hiberix (BIOLOGICAL), Prevenar 13 (BIOLOGICAL).
Who is sponsoring clinical trial NCT03207750?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.